59-05-2 Usage
Uses
Used in Oncology:
Methotrexate is used as an anti-cancer agent for the treatment of severe lymphatic leukemia, choriocarcinoma, non-Hodgkin’s lymphoma, bone carcinoma, and tumors of the head, neck, breast, and lung. It works by inhibiting the synthesis of DNA, RNA, and proteins, thereby stopping the growth of cancer cells.
Used in Rheumatology:
Methotrexate is used as an antirheumatic medication to treat autoimmune diseases such as rheumatoid arthritis, psoriasis, and lupus. It helps to reduce inflammation and slow down the progression of these diseases.
Used as a Dietary Supplement:
Methotrexate can also be used as a dietary supplement due to its ability to cross the blood-brain barrier, which may provide potential anxiolytic and vasodilator activities.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, Methotrexate is used as a folic acid antagonist, making it a valuable compound for the development of new drugs and therapies for various diseases, including cancer and autoimmune disorders.
Treatment of cancer and rheumatoid arthritis
Methotrexate is a drug used for the treatment of cancer, also known as cytotoxic drugs. In order to reduce its cytotoxicity, it can be used in conjunction with calcium leucovorin. It is primarily used for the treatment of acute leukemia (acute lymphocytic leukemia), breast cancer, malignant mole and choriocarcinoma, head and neck cancer, bone cancer, leukemia, spinal cord meningeal infiltration, lung cancer, reproductive system cancer, liver cancer, refractory psoriasis vulgaris, dermatomyositis, body myositis, ankylosing spondylitis inflammation, Crohn's disease, psoriasis and psoriatic arthritis, Behcet's disease and autoimmune disease.
In Rheumatic Arthritis:
Methotrexate is an immunosuppressant and can be used for easing the process of rheumatism with a particularly excellent efficacy in treating synovial inflammation of rheumatoid arthritis and is the most frequently used drugs for treating rheumatoid diseases.
Methotrexate (MTX), is one of first line DMARDs(disease-modifying antirheumatic drugs).The order of agent selection is not clearly defined, but MTX is often chosen initially because long-term data suggest superior outcomes compared with other DMARDs and lower cost than biologic agents.
MTX inhibits cytokine production and purine biosynthesis, which may be responsible for its antiinflammatory properties. Its onset is relatively rapid (as early as 2 to 3 weeks), and 45% to 67% of patients remained on it in studies ranging from 5 to 7 years.
Toxicities are GI (stomatitis, diarrhea, nausea, vomiting), hematologic (thrombocytopenia, leukopenia), pulmonary (fibrosis, pneumonitis), and hepatic (elevated enzymes, rare cirrhosis). MTX is contraindicated in pregnant and nursing women, chronic liver disease, immunodeficiency, pleural or peritoneal effusions, leukopenia, thrombocytopenia, preexisting blood disorders, and creatinine clearance <40 mL/min.
History of discovery
Methotrexate is the first effective anti-metabolites for treatment of tumor with good efficacy in treating choriocarcinoma and acute lymphoblastic leukemia. In 1940s, the scientists discovered that the active ingredient of Lactobacillus casei in inhibiting mice tumor-transplanted sarcoma S180 and spontaneous breast cancer is pterin tri-glutamic acid with the later one having a weak anti-folate effect.
It has also observed of bone marrow suppression upon lack of folic acid. Folic acid can promote the development of leukemia. Therefore, people initially tried to identify anti-cancer drugs from folate antimetabolites. In 1947, aminopterin had been subject to clinical trials and found to be effective in treating childhood leukemia. Then it was found of that methotrexate has high therapeutic index in treating the mouse leukemia L1210. In 1950s, it had been applied to the clinical trial and had quickly substituted the aminopterin for the treatment of leukemia and had been later further expanded for treating other tumors. It has been one of the most intensively studied anticancer drugs.
In the field of rheumatoid, though in 1951, Gubner had successfully applied aminopterin for the methotrexate treatment of rheumatoid arthritis and psoriasis. However, at the time, methotrexate was still considered as the anti-metabolic anti-cancer drugs, therefore, it is natural that people think it has a really high toxicity. Another reason is the emergence of hormones, resulting in almost all the attention being focused on hormone therapy. Only a few researchers in the field of rheumatology include Rex Hoffmeister et al had began to apply a small dose of methotrexate for treatment of autoimmune diseases.
The above information is edited by the lookchem of Dai Xiongfeng.
Immunosuppressants
Methotrexate is an anti-folate anti-metabolite with a strong immunosuppressive effect. It is first anti-folate agents that have been successfully applied to clinical field. It is effective for not only treating leukemia but also for treating solid tumors and is a kind of basic clinical anti-tumor drugs. Methotrexate can selectively act on the proliferation of cells, preventing cell division and proliferation of immune mother cells. It has inhibitory effect against humoral and cellular immunity and also has strong anti-inflammatory effect. It has inhibitory effect on the primary immune response and secondary immune response, delayed hypersensitivity and graft-versus-host reaction. Applying medication at the same time of antigen-stimulation or after one to two days can yield the strongest immunosuppressive medication with being invalid prior to antigen stimulation. Clinically it is mainly used in treatment of autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus and dermatomyositis. In addition, methotrexate is also effective for treating acute leukemia, choriocarcinoma, osteosarcoma, breast cancer, and testicular cancer and so on. It is a commonly used cycle specific drugs in combination chemotherapy.
Pharmacological effects
Methotrexate is an antifolate antineoplastic drug with inhibitory effect on a variety of animal tumor. Experiments have shown that this drug work through competitive inhibition on the dihydrofolate reductase. Dihydrofolate reductase is a key enzyme in DNA synthesis, and in particular being indispensable in the process of conversion of folate to tetrahydrofolate and deoxyuridine methylation into thymidine. This drug can selectively act on the DNA synthesis period (i.e. S phase), belonging to a cycle specific drugs. Recently it has been considered that the product has a second point of action, namely G1/S transition period; it can also inhibit IL-2 synthesis and neutrophil chemotaxis, therefore having immunosuppressive and anti-inflammatory effects. Upon large doses, it can further have direct toxicity on non-proliferating cells especially liver cells. It is clinically commonly used in as an antidote.
Methotrexate (MTX for short) has a similar structure as folic. The 4’ hydroxy and 10’ hydrogen in NH respectively correspond to the NH3 group and CH3 in the MTX. MTX can bind with the dihydrofolate reductase, blocking the reduction of folate and dihydrofolate into activated form of tetrahydrofolate, thereby inhibiting the intracellular one-carbon transfer, and affecting the newly synthesized purine nucleotide and conversion of deoxyuridine to deoxythymidine nucleotides, further blocking the DNA and RNA synthesis. The plasma concentration of MTX is 10-8mol/L, and can effectively block the incorporation of deoxyuridine into DNA via deoxythymidine nucleotide with the inhibitory concentration of purine synthesis being 10-7mol/L. The combination of MTX with dihydrofolate reductase is reversible but very strong. In order to fight against the binding of MTX, dihydrofolate should have an at least 1000 fold as high as MTX. In vitro, when MTX is less than the concentration of complete inhibition of DNA synthesis, it can induce the differentiation of human choriocarcinoma cell, increasing the generation of human chorionic gonadotropin. MTX is a cell cycle-specific drug with its major effect acting on S-phase cell with specific effect on the G1 phase as well and having delayed effect on the G1/S.
Pharmacokinetics
This product has an excellent oral absorption with the plasma concentration reaching peak after 30~60min. Large-dose administration or simultaneous administration without food yield a poor absorption. After intramuscular injection, the blood concentration can be maintained for a longer period with drug disappearing slowly after intrathecal injection, the cerebrospinal fluid concentration can be maintained for about 6d. This product, after absorption, has 60% to 85% for binding with plasma protein. Simultaneously taking aspirin or sulfa drugs can lead to high blood concentration of this product with consequent increase in both efficacy and toxicity. Poor kidney function may also increase the toxicity of this product. A small amount of this product can be able to penetrate through the blood-brain barrier. This drug is mainly distributed in the liver, kidney with also a fraction existing in the main bone marrow. Drug has plasma half-life of 2h. Drug is primarily excreted in the prototype by the urine with the urine excretion amount being 90% within 48h while excretion amount of biliary and fecal being minimal.
Clinical application
It is effective in treating acute leukemia with better efficacy in pediatric patients. It has a good efficacy in treating choriocarcinoma and malignant mole. Large dose administration is effective in treating osteosarcoma, soft tissue sarcoma, lung cancer, testicular cancer, breast cancer, and ovarian cancer. It is also effective in treating head and neck cancer, liver cancer and gastrointestinal cancer. Arterial infusion of this product has goo efficacy in treating head and neck cancer and liver cancer. However, it is rarely used for treating psoriasis and psoriasis.
Dosage
1, early treatment of leukemia usually applies multiple dose of treatment; adult oral 2.5~10 mg/d with total amount of 50~150 mg. Children: 1.25~5mg/d, tend to apply large-scale intermittent dosing regimen, administered therapy, oral administration or intramuscular injection 2 times per week with 0.25~0.75 mg/kg at each time; adults usually take 20~25 mg per time; sheath injection of 10~15 mg/time; children: 6~12mg/times according to the ages; for therapeutic use once a day and continue for 3 d; for prevention, apply once every 4-8 weeks.
2, Choriocarcinoma, adult: 10~30mg; use intramuscular injection or oral administration once daily for continuous 5d. You can repeat the treatment course according to the reaction of the patient.
3, solid cancer, preferably for continuous arterial infusion while giving intermittent intramuscular injection of leucovorin (CF); the usual dose is 25~50mg/d, CF6~9mg, apply intramuscular injection once every 4~6h.
4, apply large-dose for treating osteosarcoma and combine with CF detoxification. The general dose of this product is generally 3~20g/m2. It can be dissolved in 500~1000 mL of 5% glucose injection for intravenous infusion of 4h. After dropping of 2~6h, you can begin to use CF with a dose of 6~12mg for intramuscular injection (or oral) once each 6h for a total of 3 d. In order to ensure that the drug can be rapidly excreted from the body, we should replenish electrolytes, water and sodium bicarbonate at I d before or every 1~2d during the infusion to make the daily urine output be over 3000ml and ensure that it is alkaline. For the blood and plasma concentration of methotrexate, liver function, and kidney function, we should apply daily inspection.
5, treatment of psoriasis has been rarely applied due to side effects. For treating psoriasis, orally administer 1.25 mg per time with 2 to 3 times per day and 6~9d as a course of treatment.
Adverse reactions and precautions
1. Gastrointestinal reactions include oral mucosal erosion, ulcers, vomiting, and diarrhea with blood in the stool being observed in severe cases.
2. Inhibition of bone marrow granulocyte system with pancytopenis happening in severe cases.
3. Excessive head and neck artery injection or intrathecal injection can cause convulsions.
4. high-dose or long-term medication can cause liver and kidney damage.
5. Additionally, there are hair loss, rashes, and pigmentation, exfoliative dermatitis may also occur; in a few conditions, reproductive dysfunction, irregular menstruation can be observed. It can cause teratogenic fetus or abortion during the early half of pregnancy.
6. Upon intrathecal injection, systemic administration should be paused in order to avoid accumulation of drug for poisoning.
7. Patients of liver and kidney dysfunction should be disabled; pregnant women should take with caution.
8. Salicylates, sulfonamides, phenytoin, tetracycline, chloramphenicol and aminobenzoic acid can enhance the efficacy of the drug with folic acid may reduce the efficacy of the drug.
Drug Interactions
1, Alcohol and other drugs which can cause liver damage, if used in combination with this product, may further increase liver toxicity.
2, since methotrexate can cause increased blood uric acid levels, for patients with gout or hyperuricemia, you should respectively increase the dose of allopurinol and colchicine.
3, the product can enhance the anti-clotting effect, and can even cause lack of liver coagulation factors (and) thrombocytopenia, and therefore we should be cautious for using it in combination with other anticoagulants.
4, with the simultaneous administration of Phenylbutazone and sulfa drugs, because of it competition with protein binding, this product may cause increased serum concentration and lead to toxicity.
5, Oral administration of the kanamycin can increase the absorption of this drug upon oral administration, and oral neomycin may reduce its absorption.
6, Combination with a weak organic acid and salicylate can inhibit the renal excretion of this product, further resulting in increased serum concentrations of the drug. We should reduce the dosage appropriately according to the actual case.
7, Drugs like triamterene and pyrimethamine can have anti-folate effects with simultaneous use of this product being able to increase its side effects.
8, Combination with fluorouracil or first using fluorouracil before administering this drug can both produce antagonism. But if first use this drug and then administer fluorouracil after 4~6h can have synergistic effect. Similarly, this drug, if being used in combination with L-asparaginase can also lead to reduced efficiency, as with the latter 10 days or within 24h after administration of this product to L-asparaginase Instead applying the L-asparaginase at ten days after using the later one or at 24 h within using this product can enhance the efficacy and reduce its side effects on the digestive tract and bone marrow. It has been reported recently applying cytarabine at 24 h before using this product or 10 mins after can increase the anti-cancer activity of this product. We should be cautious when applied methotrexate in combination with radiotherapy or other kinds of drugs on bone marrow suppression.
Production method
It is obtained from the cyclization between 2, 4, 5, 6-tetraaminopyrimidine and dibromo propionaldehyde and further condensation with p-N-Methylaminobenzoylglutamic acid.
Originator
Methotrexate Lederle,Lederle,US,1955
Indications
Methotrexate is approved for use in severe disabling
psoriasis recalcitrant to other less toxic treatments. The
standard regimen is similar to low-dose therapy used
for the treatment of rheumatoid arthritis . Although toxicities are similar to those described in
the treatment of other diseases, hepatic cirrhosis and
unexpected pancytopenia are of special concern given
the chronicity of treatment.
Indications
Of the DMARDs, methotrexate (Rheumatrex) is the
most widely prescribed. It is indicated for the treatment
of rheumatoid arthritis and psoriasis; it is also used for
psoriatic arthritis, systemic lupus erythematosus, and sarcoidosis. It is generally as efficacious as the other
agents, with a low incidence of serious side effects when
prescribed on a low-dose weekly schedule.
Indications
Methotrexate competitively inhibits the binding of folic
acid to the enzyme dihydrofolate reductase.
Tetrahydrofolate is in turn converted to N5,N10-
methylenetetrahydrofolate, which is an essential cofactor
for the synthesis of thymidylate, purines, methionine,
and glycine. The major mechanism by which
methotrexate brings about cell death appears to be inhibition
of DNA synthesis through a blockage of the
biosynthesis of thymidylate and purines.
Cells in S-phase are most sensitive to the cytotoxic effects
of methotrexate. RNA and protein synthesis also
may be inhibited to some extent and may delay progression
through the cell cycle, particularly from G1 to S.
Indications
Methotrexate, for example, is highly
bound to serum albumin and can be displaced by salicylates,
sulfonamides, phenothiazines, phenytoin, and
other organic acids. The induction of hepatic drugmetabolizing
enzymes by phenobarbital may alter the
metabolism of cyclophosphamide to both active and inactive
metabolites. Mercaptopurine metabolism is
blocked by allopurinol, an occurrence that may result in
lethal toxicity if the dosage of mercaptopurine is not reduced
to one-fourth of the usual dosage. Methotrexate
is secreted actively by the renal tubules, and its renal
clearance may be delayed by salicylates.
Manufacturing Process
5 g (15 mmol) of diethyl-p-methylaminobenzoyl-L-glutamate and 8.0 g of aminomalononitrile tosylate (65% by NMR assay, 20 mmol) were dissolved in warm ethanol (65 ml, with 15% water by volume). To this solution, cooled to 0°C, was added all at once and with vigorous stirring, 3.6 g of βbromopyruvaldoxime (89% by NMR assay, 19 mmol). After 30 minutes the stirred mixture, which was allowed to warm slowly to room temperature, was neutralized with powdered NaHCO3 to pH 6, stirring continued for four additional hours, and the resulting mixture filtered through Celite. The filtrate was evaporated under reduced pressure to a glasslike substance, which was taken up in 500 ml of chloroform. The resulting suspension was then filtered using Celite, and the filtrate was washed with water, dried with anhydrous MgSO4, and evaporated to give an orange glasslike substance which was used directly in the next step.To a 20% solution of titanium trichloride in water (39 mmol), stirred under
nitrogen, was added a solution of 18 g (230 mmol) of ammonium acetate in
55 ml of water. Then, to this mixture, cooled to 10°C and stirred with an airdriven stirrer, was added over a period of 5 minutes a solution of the orange
glassy substance above distilled in 60 ml of tetrahydrofuran. The mixture was
vigorously stirred for 15 minutes while a rapid stream of nitrogen was passed
through. After this time, 15 g of powdered sodium sulfite (120 mmol) was
added to the mixture, which after several minutes turned from green to
yellowish white. This mixture was stirred into 1 liter of chloroform, and the
heavy yellow layer separated by use of a separatory funnel. This chloroform
layer was washed with water, dried using anhydrous MgSO4, and evaporated
under reduced pressure to give a light orange glass, which was then
chromatographed rapidly on a column made from 80 g of Baker silica gel,
using 5% ethyl acetate in chloroform as the eluent.The product obtained by evaporation of the eluate was recrystallized from
ethanol-ether (1:10) to give a light yellow powder, MP 85 to 88°C. The yield
was 4.4 g (63%).A solution containing 4.8 g (10.2 mmol) of diethyl-N-[p-[[(2-amino-3-cyano5-pyrazinyl)methyl] methylamino]benzoyl]glutamate and 5 g (42 mmol) of
guanidine acetate in 40 ml of dimethylformamide was stirred under nitrogen
at 120°C for six hours. The resulting solution was cooled to room
temperature, filtered and evaporated to a glassy product using a rotary
evaporator and a mechanical vacuum pump to insure a better vacuum. The
residual glass was taken up in 500 ml of chloroform, the resulting suspension
filtered using Celite, and the filtrate washed with water, dried using anhydrous
MgSO4, and evaporated to dryness. (The residual material was
chromatographed rapidly on a column prepared from 250 g of Baker silica gel
using, initially, 2% ethanol in chloroform, and then 5% ethanol in chloroform
as eluents.) The material obtained by evaporation of the eluates was
crystallized from ethanol-chloroform (4:1) to give small, pale yellow lustrous
platelets, MP 142°C to 154°C; yield, 3.8 g (73%). Further crystallization of this material from ethanol-chloroform (4:1) raised the MP to 153°C to 155°C.
The compound is completely racemic.A sample of this product was hydrolyzed in a mixture of water and methanol
in the presence of potassium hydroxide. Essentially pure methotrexate was
thus obtained.
Therapeutic Function
Antineoplastic
Biological Functions
Although the mechanism of
action of methotrexate in rheumatoid arthritis is unknown, recent studies have shown that methotrexate reversibly
inhibits dihydrofolate reductase, blocking the proliferation of B cells by interfering with DNA synthesis, repair, and
replication. Oral absorption is dose-dependent, being well-absorbed at doses of 7.5–25 mg once a week. At this
dose, oral bioavailability is approximately 60%, and food can delay absorption and reduce peak concentration. The
volume of distribution is 0.4 to 0.8 L/kg. Protein binding is approximately 50%. It is metabolized to active metabolites,
methotrexate polyglutamates and 7-hydroxymethotrexate. Some metabolism occurs by intestinal flora after oral administration.
Methotrexate is actively transported into the urine (80–90% unchanged in the urine within 24 hours) via the folate
transporter, an organic anion transporter. Its elimination half-life is 3 to 10 hours.
Acquired resistance
Mammalian cells have several mechanisms of resistance
to methotrexate. These include an increase in intracellular
dihydrofolate reductase levels, appearance
of altered forms of dihydrofolate reductase with decreased
affinity for methotrexate, and a decrease in
methotrexate transport into cells. The
relative importance of each of these mechanisms of resistance
in various human tumors is not known.
Cellular uptake of the drug is by carrier-mediated
active transport. Drug resistance due to decreased
transport can be overcome by greatly increasing extracellular
methotrexate concentration, which provides a
rationale for high-dose methotrexate therapy. Since
bone marrow and gastrointestinal cells do not have impaired
folate methotrexate transport, these normal cells
can be selectively rescued with reduced folate, bypassing
the block of dihydrofolate reductase. Leucovorin
(citrovorum factor, folinic acid, 5-formyltetrahydrofolate)
is the agent commonly used for rescue.
Air & Water Reactions
Methotrexate is sensitive to hydrolysis, oxidation and light. Insoluble in water.
Reactivity Profile
Methotrexate decomposes in very acidic or alkaline conditions. Methotrexate is incompatible with strong oxidizing agents and strong acids.
Hazard
Very toxic. Questionable carcinogen.
Fire Hazard
Flash point data for Methotrexate are not available; however, Methotrexate is probably combustible.
Biological Activity
Cytotoxic agent. Inhibits thymidylate synthetase and de novo purine synthesis. Potent folic acid antagonist; inhibits dihydrofolate reductase. Also inhibits Ras carboxyl methylation in DKOB8 cells, leading to decreased p44 and Akt activation.
Mechanism of action
Methotrexate is a folic acid antagonist structurally designed to compete successfully with 7,8-DHF for the DHFR enzyme. The direct inhibition of DHFR causes cellular levels of 7,8-DHF to build up, which in turn results in feedback (indirect) inhibition of thymidylate synthase. Methotrexate also is effective in inhibiting glycine amide ribonucleotide (GAR) transformylase , a key enzyme in the synthesis of purine nucleotides. Take note of the structural differences between methotrexate and DHF, because these differences will be important to an understanding of the chemical mechanism of this anticancer agent.
Pharmacology
Methotrexate is well absorbed orally and at usual
dosages is 50% bound to plasma proteins. The plasma
decay that follows an intravenous injection is triphasic,
with a distribution phase, an initial elimination phase,
and a prolonged elimination phase. The last phase is
thought to reflect slow release of methotrexate from tissues.
The major routes of drug excretion are glomerular
filtration and active renal tubular secretion.
The formation of polyglutamic acid conjugates of
methotrexate has been observed in tumor cells and in
the liver and may be an important determinant of cytotoxicity.
These methotrexate polyglutamates are retained
in the cell and are also potent inhibitors of dihydrofolate
reductase.
Pharmacology
Methotrexate is a folate antimetabolite that inhibits dihydrofolate
reductase and other folate-dependent enzymes
in cells. At the low doses used in the therapy
of rheumatoid arthritis,methotrexate appears to be acting
more as an antiinflammatory agent than as an immunosuppressant.
Methotrexate inhibits folate-dependent
enzymes involved in adenosine degradation,
increasing concentrations of extracellular adenosine.
Adenosine acts via cell surface receptors to inhibit the
production of inflammatory cytokines such as TNF-α
and IFN-γ.Methotrexate also decreases the production
of inflammatory prostaglandins and proteases, though a
direct action on the COX enzymes has not been noted.
Clinical Use
Methotrexate is part of curative combination
chemotherapy for acute lymphoblastic leukemias,
Burkitt’s lymphoma, and trophoblastic choriocarcinoma.
It is also useful in adjuvant therapy of breast carcinoma;
in the palliation of metastatic breast, head, neck,
cervical, and lung carcinomas; and in mycosis fungoides.
High-dose methotrexate administration with leucovorin
rescue has produced remissions in 30% of patients
with metastatic osteogenic sarcoma.
Methotrexate is one of the few anticancer drugs that
can be safely administered intrathecally for the treatment
of meningeal metastases. Its routine use as prophylactic
intrathecal chemotherapy in acute lymphoblastic
leukemia has greatly reduced the incidence
of recurrences in the CNS and has contributed to the
cure rate in this disease. Daily oral doses of methotrexate
are used for severe cases of the nonneoplastic skin
disease psoriasis, and methotrexate
has been used as an immunosuppressive agent in severe
rheumatoid arthritis.
Side effects
Myelosuppression is the major dose-limiting toxicity
associated with methotrexate therapy. Gastrointestinal
toxicity may appear in the form of ulcerative mucositis
and diarrhea. Nausea, alopecia, and dermatitis are common
with high-dose methotrexate. The greatest danger
of high-dose therapy is renal toxicity due to precipitation
of the drug in the renal tubules, and the drug should
not be used in patients with renal impairment. Intrathecal
administration may produce neurological toxicity
ranging from mild arachnoiditis to severe and progressive
myelopathy or encephalopathy. Chronic lowdose
methotrexate therapy, as used for psoriasis, may
result in cirrhosis of the liver. Occasionally methotrexate
produces an acute, potentially lethal lung toxicity
that is thought to be allergic or hypersensitivity
pneumonitis. Additionally, methotrexate is a potent teratogen
and abortifacient.
Side effects
In the low-dose regimen used for rheumatoid arthritis,
most side effects of methotrexate are mild and can be
managed by temporarily stopping the drug or reducing
the dose. These include nausea, stomatitis, GI discomfort,
rash, diarrhea, and headaches. Changes in liver
aminotransferases and mild to moderate immunosuppression
have been reported in rheumatoid arthritis patients
taking methotrexate. Severe toxicity is possible
but rare and may be a function of drug accumulation.
These effects include hepatotoxicity progressing to cirrhosis,
pneumonitis progressing to pulmonary fibrosis,
and bone marrow depression with anemia, leukopenia,
and thrombocytopenia. Folic acid supplementation is often
used to alleviate certain side effects of methotrexate
therapy (stomatitis, GI irritation, hematopoietic effects)
but may also contribute to resistance to this therapy.
Synthesis
Methotrexate, N-[p-[[2,4-diamino-6-piperidinyl)methyl]methylamino]-
benzoyl]-L-()-glutamic acid (30.1.1.8), is made by reacting N-(4-methylaminobenzoyl)glutaminic acid (30.1.1.3) with 2-amino-4-hydroxyl-6-bromomethylpteridine(30.1.1.7). In order to do this, N-(4-methylaminobenzoyl)glutaminic acid (30.1.1.3) is synthesized from 4-nitrobenzoyl chloride, which is reacted with L-glutamic acid, forming
N-(4-nitrobenzoyl)glutamic acid (30.1.1.1), the nitro group of which is reduced to an
amino group using hydrogen over Raney nickel, which gives N-(4-aminobenzoyl)glutamic
acid (30.1.1.2). This undergoes reductive methylation using formaldehyde and hydrogen,
which forms N-(4-methylaminobenzoyl)glutamic acid (30.1.1.3).
The second part of the methotrexate molecule, 2-amino-4-hydroxy-6-bromomethylpteridine (30.1.1.7), is made from 2,4,6-triaminopyrimidine (30.1.1.4), which is easily synthesized by reacting malonic acid dinitrile with guanidine. This is nitrosylated by anhydrous
nitrous acid to 2,4,6-triamino-5-nitrosopyrimidine (30.1.1.5), and then it is reduced by
sodium borohydride to 2,4,5,6-tetraaminopyrimidine (30.1.1.6). Upon reacting this with 1,2-
dibromopropionic aldehyde, the product of attaching bromine to acrolein, 2-amino-4-
hydroxy-6- bromomethyl-pteridine (30.1.1.7) is formed. Alkylating the amine nitrogen atom
of N-(4-methylaminbenzoyl)glutamic acid (30.1.1.3) with resulting bromide (30.1.1.7) gives
methotrexate (30.1.1.8).
Potential Exposure
Methotrexate is an alkaloid anticancer
drug available in tablet or injectable liquid form. A chemotherapy drug that interferes with DNA and RNA synthesis.
It is also an insect chemosterilant.
Veterinary Drugs and Treatments
Indicated for lymphomas and some solid tumors in dogs and cats. In human medicine, methotrexate
is also being used to treat refractory rheumatoid arthritis
and severe psoriasis.
Drug interactions
Potentially hazardous interactions with other drugs
Anaesthetics: antifolate effect increased by nitrous
oxide - avoid.
Analgesics: increased risk of toxicity with NSAIDs
- avoid.
Antibacterials: absorption possibly reduced
by neomycin; antifolate effect increased with
co-trimoxazole and trimethoprim; penicillins
and possibly ciprofloxacin reduce excretion
of methotrexate (increased risk of toxicity);
increased haematological toxicity with doxycycline,
sulphonamides and tetracycline.
Antiepileptics: concentration possibly increased by
levetiracetam.
Antimalarials: antifolate effect enhanced by
pyrimethamine.
Antipsychotics: avoid with clozapine (increased risk
of agranulocytosis).
Ciclosporin: methotrexate may inhibit the clearance
of ciclosporin or its metabolites; ciclosporin may
inhibit methotrexate elimination.
Corticosteroids: increased risk of haematological
toxicity.
Cytotoxics: effects of methotrexate antagonised by
asparaginase, crisantaspase and pegasparagase -
give asparaginase, crisantaspase and pegasparagase
24 hours after methotrexate; increased pulmonary
toxicity with cisplatin.
Leflunomide: risk of toxicity.
Probenecid: excretion of methotrexate reduced.
Retinoids: concentration increased by acitretin, also
increased hepatotoxicity - avoid.
Ulcer-healing drugs: PPIs may reduce high dose
methotrexate elimination; consider temporarily
stopping PPI
Metabolism
Methotrexate can be given orally in the treatment of breast, head and neck, and various lung cancers as well as in non-Hodgkin's lymphoma. The sodium salt form also is marketed for IV, intramuscular, intra-arterial, or intrathecal injection. Oral absorption is dose-dependent and peaks at 80 mg/m2 because of site saturation. The monoglutamate tail of methotrexate permits active transport into cells, with carrier-mediated transport predominating at serum concentration levels lower than 100 μM. Once inside the cell, methotrexate undergoes a polyglutamation reaction that adds several anionic carboxylate groups to trap the drug at the site of action. Polyglutamation is more efficient in tumor cells than in healthy cells and, therefore, may promote selective toxicity of this drug. Cancer cells can become resistant to methotrexate over time which may involve impaired transport across tumor cell membranes, enhanced efflux from the tumor cell, and attenuated polyglutamation rates. The polyglutamated drug will be hydrolyzed back to the parent structure before renal elimination. Up to 90% of an administered dose of methotrexate is excreted unchanged in the urine within 24 hours.
Shipping
UN1544 Alkaloids, solid, n.o.s. or Alkaloid salts,
solid, n.o.s. poisonous, Hazard Class: 6.1; Labels: 6.1-
Poisonous materials, Technical Name Required. UN2811
Toxic solids, organic, n.o.s., Hazard Class: 6.1; Labels: 6.1-
Poisonous materials, Technical Name Required.
Purification Methods
Most common impurities are 10-methylpteroylglutamic acid, aminopterin and pteroylglutamic acid. Purify it by chromatography on Dowex-1 acetate, followed by filtration through a mixture of cellulose and charcoal. It has been recrystallised from aqueous HCl or by dissolution in the minimum volume of N NaOH and acidified until precipitation is complete, filter or better collect by centrifugation, wash with H2O (also by centrifugation) and dry at 100o/3mm. It has UV: max at 244 and 307nm ( 17300 and 19700) in H2O at pH 1; 257, 302 and 370nm ( 23000, 22000 and 7100) in 2O at pH 13. [Momle Biochemical Preparations 8 20 1961, Seeger et al. J Am Chem Soc 71 1753 1949.] It is a potent inhibitor of dihydrofolate reductase and is used in cancer chemotherapy. [Blakley The Biochemistry of Folic Acid and Related Pteridines, North-Holland Publ Co., Amsterdam, NY, pp157-163 1969, Beilstein 26 IV 3833.] It is CARCINOGENIC; HANDLE WITH EXTREME CARE.
Incompatibilities
Combustible. Compounds of the carboxyl group react with all bases, both inorganic and
organic (i.e., amines) releasing substantial heat, water and a
salt that may be harmful. Incompatible with arsenic compounds (releases hydrogen cyanide gas), diazo compounds,
dithiocarbamates, isocyanates, mercaptans, nitrides, and
sulfides (releasing heat, toxic, and possibly flammable
gases), thiosulfates and dithionites (releasing hydrogen sulfate and oxides of sulfur). Incompatible with oxidizers
(chlorates, nitrates, peroxides, permanganates, perchlorates,
chlorine, bromine, fluorine, etc.); contact may cause fires or
explosions. Keep away from alkaline materials, strong bases,
strong acids, oxoacids, epoxides, light, UV, moisture.
Waste Disposal
It is inappropriate and possibly dangerous to the environment to dispose of expired or
waste drugs and pharmaceuticals by flushing them down
the toilet or discarding them to the trash. Household quantities of expired or waste pharmaceuticals may be mixed
with wet cat litter or coffee grounds, double-bagged in
plastic, discard in trash. Larger quantities shall carefully
take into consideration applicable DEA, EPA, and FDA
regulations. If possible return the pharmaceutical to the
manufacturer for proper disposal being careful to properly
label and securely package the material. Alternatively, the
waste pharmaceutical shall be labeled, securely packaged and transported by a state licensed medical waste contractor
to dispose by burial in a licensed hazardous or toxic waste
landfill or incinerator.
Precautions
Methotrexate is teratogenic and is contraindicated duringpregnancy and breast-feeding. Prior to attemptingpregnancy, women should wait at least one menstrualcycle and men at least 3 months after discontinuing thisdrug. Additional contraindications to methotrexate administrationinclude kidney, liver, and lung disease;moderate to high alcohol use; immunodeficiency; blooddyscrasias; and hypersensitivity. Elderly persons may be at increased risk for toxicity because of decreased renaland hepatic function.Methotrexate clearance can be decreased by thecoadministration of NSAIDs; however, this not usuallya problem with the low doses of methotrexate used totreat arthritis. Methotrexate can be displaced fromplasma protein binding sites by phenylbutazone, phenytoin,sulfonylureas, and sulfonamides and certain otherantibiotics. The antifolate effects of methotrexate areadditive with those of other folate-inhibitory drugs,such as trimethoprim.
Check Digit Verification of cas no
The CAS Registry Mumber 59-05-2 includes 5 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 2 digits, 5 and 9 respectively; the second part has 2 digits, 0 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 59-05:
(4*5)+(3*9)+(2*0)+(1*5)=52
52 % 10 = 2
So 59-05-2 is a valid CAS Registry Number.
InChI:InChI=1/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)/t13-/m1/s1
59-05-2Relevant articles and documents
METHOTREXATE ANALOGS AND METHODS OF USE
-
, (2022/01/04)
Compounds having general formula (I) or a pharmaceutically acceptable salt, N-oxide, or hydrate thereof are provided herein. Also provided are methods of making the compounds and methods of their use, including in treatment of cancer, autoimmune disorders, and viral infections.
Synthesis process of methotrexate
-
Paragraph 0045-0088; 0101; 0110-0115, (2021/05/29)
The invention relates to a synthesis process of methotrexate, which comprises the following steps: synthesizing a methotrexate crude product, preparing the synthesized methotrexate crude product into methotrexate disodium salt, adjusting the pH value to 5-6, and refining into a methotrexate pure product, the reaction synthesis steps are less, the raw materials are easy to purchase, the cost is low, and the experimental operation is simple; the methotrexate disodium salt is recrystallized and separated out by acetone, the yield is improved, and the purity of the compound after detection reaches 99% or above.
A preparation method of methotrexate (by machine translation)
-
Paragraph 0079-0084; 0093-0098; 0099-0104; 0105-0110, (2019/04/26)
The invention provides a preparation method of methotrexate, including: A) 6 - bromomethyl pterin and to the methylamino benzoyl glutamate in the solvent in the reaction, the obtained solid product; the to the methylamino benzoyl glutamate is selected from methylamino benzoyl glutamic acid zinc salt, to the methylamino benzoyl glutamic acid calcium salt and to the methylamino benzoyl glutamic acid magnesium salt in one or several kinds of; the solvent is selected from the HBr and/or HI; B) the solid product soluble in aqueous solution, adjusting the pH value, to obtain the crude product of methotrexate; C) for purifying the crude product obtained methotrexate methotrexate. The invention will be 6 - bromomethyl pterin and to the methylamino benzoyl glutamate in the HBr and/or HI the solvent in the reaction, choose the specific reaction raw materials and specific reaction solvent, combined with a specific refining process for the preparation of the methotrexate high purity and yield and, at the same time the invention simple preparation method, raw material sources are extensive, favorable to industrial production. (by machine translation)
Synthesis and Evaluation of Hydrogen Peroxide Sensitive Prodrugs of Methotrexate and Aminopterin for the Treatment of Rheumatoid Arthritis
Peiró Cadahía, Jorge,Bondebjerg, Jon,Hansen, Christian A.,Previtali, Viola,Hansen, Anders E.,Andresen, Thomas L.,Clausen, Mads H.
, p. 3503 - 3515 (2018/05/01)
A series of novel hydrogen peroxide sensitive prodrugs of methotrexate (MTX) and aminopterin (AMT) were synthesized and evaluated for therapeutic efficacy in mice with collagen induced arthritis (CIA) as a model of chronic rheumatoid arthritis (RA). The prodrug strategy selected is based on ROS-labile 4-methylphenylboronic acid promoieties linked to the drugs via a carbamate linkage or a direct C-N bond. Activation under pathophysiological concentrations of H2O2 proved to be effective, and prodrug candidates were selected in agreement with relevant in vitro physicochemical and pharmacokinetic assays. Selected candidates showed moderate to good solubility, high chemical and enzymatic stability, and therapeutic efficacy comparable to the parent drugs in the CIA model. Importantly, the prodrugs displayed the expected safer toxicity profile and increased therapeutic window compared to MTX and AMT while maintaining a comparable therapeutic efficacy, which is highly encouraging for future use in RA patients.
A sequential enzyme-activated and light-triggered pro-prodrug nanosystem for cancer detection and therapy
Chen, Zelin,Li, Bowen,Xie, Xin,Zeng, Fang,Wu, Shuizhu
, p. 2547 - 2556 (2018/05/22)
DT-diaphorase is a cytosolic flavoenzyme whose level is strongly elevated in a number of tumor types. Incorporating a DT-diaphorase's substrate in the structure of anticancer drugs may facilitate cancer detection and therapy. Herein, we developed a novel pro-prodrug nanosystem for cancer detection and therapy, which features enzyme-activated fluorescence emission and subsequent light-triggered drug release. The pro-prodrug molecule comprises an anticancer drug methotrexate (MTX), an enzyme (DT-diaphorase) responsive quinone propionic acid moiety and a light-activatable coumarinyl. In the absence of DT-diaphorase, the quinone propionic acid moiety quenches the fluorescence of coumarin via photoinduced electron transfer (PET) and blocks the photocleavage pathway. DT-diaphorase can annihilate the effect of PET and restore the fluorescence of coumarin. This fluorescence serves as the reporting signal for assessing the enzyme biomarker level and discriminates tumor cells from normal cells, and subsequently photocontrollable release of the active drug, MTX, can be activated via one- or two-photon irradiation. This pro-prodrug nanosystem shows strong cytotoxicity toward cancer cells and a negligible effect on normal cells. This strategy provides a new platform for constructing nanosystems for cancer detection and subsequent on-demand selective killing of cancer cells via both internal- and external-stimuli activation.
A photochemical approach for controlled drug release in targeted drug delivery
Choi, Seok Ki,Verma, Manisha,Silpe, Justin,Moody, Ryan E.,Tang, Kenny,Hanson, Jeffrey J.,Baker Jr., James R.
experimental part, p. 1281 - 1290 (2012/04/10)
Photochemistry provides a unique mechanism that enables the active control of drug release in cancer-targeting drug delivery. This study investigates the light-mediated release of methotrexate, an anticancer drug, using a photocleavable linker strategy based on o-nitrobenzyl protection. We evaluated two types of the o-nitrobenzyl-linked methotrexate for the drug release study and further extended the study to a fifth-generation poly(amidoamine) dendrimer carrier covalently conjugated with methotrexate via the o-nitrobenzyl linker. We performed the drug release studies by using a combination of three standard analytical methods that include UV/vis spectrometry, 1H NMR spectroscopy, and anal. HPLC. This article reports that methotrexate is released by the photochemical mechanism in an actively controlled manner. The rate of the drug release varies in response to multiple control parameters, including linker design, light wavelength, exposure time, and the pH of the medium where the drug release occurs.
THERAPEUTIC FOR HEPATIC CANCER
-
, (2011/02/18)
A novel pharmaceutical composition for treating or preventing hepatocellular carcinoma and a method of treatment are provided. A pharmaceutical composition for treating or preventing liver cancer is obtained by combining a chemotherapeutic agent with an anti-glypican 3 antibody. Also disclosed is a pharmaceutical composition for treating or preventing liver cancer which comprises as an active ingredient an anti-glypican 3 antibody for use in combination with a chemotherapeutic agent, or which comprises as an active ingredient a chemotherapeutic agent for use in combination with an anti-glypican 3 antibody. Using the chemotherapeutic agent and the anti-glypican 3 antibody in combination yields better therapeutic effects than using the chemotherapeutic agent alone, and mitigates side effects that arise from liver cancer treatment with the chemotherapeutic agent.
Anti-Claudin 3 Monoclonal Antibody and Treatment and Diagnosis of Cancer Using the Same
-
, (2010/05/13)
Monoclonal antibodies that bind specifically to Claudin 3 expressed on cell surface are provided. The antibodies of the present invention are useful for diagnosis of cancers that have enhanced expression of Claudin 3, such as ovarian cancer, prostate cancer, breast cancer, uterine cancer, liver cancer, lung cancer, pancreatic cancer, stomach cancer, bladder cancer, and colon cancer. The present invention provides monoclonal antibodies showing cytotoxic effects against cells of these cancers. Methods for inducing cell injury in Claudin 3-expressing cells and methods for suppressing proliferation of Claudin 3-expressing cells by contacting Claudin 3-expressing cells with a Claudin 3-binding antibody are disclosed. The present application also discloses methods for diagnosis or treatment of cancers.
Leukocyte internalized peptide-drug conjugates
-
, (2008/06/13)
The invention discloses compositions and methods useful for treating and preventing autoimmune diseases. The compositions and methods utilize peptides that are cell-specific. The peptides are conjugated to drugs. The peptide-drug conjugate can be internalized by the targeted cells thereby allowing for cell-specific delivery of the drug.
Agents for corneal or intrastromal administration to treat or prevent disorders of the eye
-
, (2008/06/13)
Methods and preparations for treating disorders of the eye and/or causing dissolution of corneal proteoglycans and organized healing of corneal stroma, softening of the cornea for non-surgical refractive correction of eyesight, removing corneal haze and opacification, inhibiting fibroblasts and preventing corneal fibrosis and scar formation, treating pterigiums and treating corneal neovascularization as well as iris neovascularization. Preparations containing a) urea, b) urea derivatives (e.g., hydroxyurea, thiourea), c) antimetabolites, e) urea, urea derivatives, non-enzymatic proteins, nucleosides, nucleotides and their derivatives (e.g., adenine, adenosine, cytosine, cytadine, guanine, guanitadine, guanidinium, guanidinium chloride, guanidinium salts, thymidine, thymitadine, uradine, uracil, cysteine), reduced thioctic acid, uric acid, calcium acetyl salicylate, ammonium sulfate, isopropyl alcohol, ethanol, polyethylene glycol, polypropylene glycol or other compound capable of causing nonenzymatic dissolution of the corneal protoeglycans or f) any of the possible combinations thereof, are administered to the eye in therapeutically effective amounts.
